Despite the excellent overall diagnostic performance of algorithmic approaches, it appears that balancing methods are underutilized, resulting in worse performance for smaller tumor subgroups (e.g., 1p/19q codeleted or IDH1/2 mutated gliomas). The gene discussed is IDH1; the disease is central nervous system cancer.